Table 1. Demographic and immunological characteristics of the study subjects included in the analysis.
| Rochester cohort (n = 887) | San Diego cohort (n = 542) | Total (n = 1,429) | |
| Age at Enrollment | |||
| Median, IQRa (Years) | 15 (13, 17) | 23 (22, 27) | 17 (14, 22) |
| Age at Last Vaccination (Years) | |||
| Median, IQRa | 10 (5, 12) | 19 (18, 21) | 12 (5, 18) |
| Time from Last Vaccination to Enrollment | |||
| Median, IQRa (Years) | 6.4 (4.6, 8.5) | 3.0 (2.2, 3.9) | 5.2 (3.1, 7.5) |
| Gender (N, %) | |||
| Male | 487 (54.9%) | 394 (72.7%) | 881 (61.7%) |
| Female | 400 (45.1%) | 148 (27.3%) | 548 (38.3%) |
| Race (N, %) | |||
| Caucasian | 887 (100%) | 542 (100%) | 1,429 (100%) |
| Neutralizing Antibodies (NT50) | |||
| Median, IQRa | 55.5 (34.4, 91.3) | 62.8 (42.3, 108.3) | 58.4 (36.5, 96.6) |
| Mean, SD | 72.0 (60.9) | 94.6 (127.2) | 80.6 (92.7) |
| Range | 17.0–650.8 | 15.6–1298.0 | 15.6–1298.0 |
a
IQR, inter-quartile range with 25% and 75% quartiles.
Humoral response is defined as the rubella-specific NT50 titer in the sICNA assay. Values reported are in NT50 for antibody responses ± IQR/inter-quartile range).